Medication Description: Thioridazin (Thioridazinum)
THYORIDAZIN (Thioridazinum). 2-methylthio-10- [2- (1-methyl-2-piperidyl) ethyl] phenothiazine hydrochloride.
Synonyms: Melleril, Sonapaks, Thioril, Mallorol, Malloryl, Mellaril, Melleril, Sonapax, Thioridazine hydrochloride, Thioril.
By antipsychotic activity, thioridazine is inferior to aminazine, levomepromazine. Antipsychotic action is combined with a sedative effect without pronounced inhibition, lethargy, and emotional indifference. It has a moderate stimulating effect. Along with the neuroleptic there is a moderate thymoleptic (anti-depressive) effect. It has almost no cataleptic effect, and much less frequently than other phenothiazine preparations, causes extrapyramidal disorders.
Most effective in mental and emotional disorders, accompanied by fear, tension, agitation.
In psychiatric practice, they are used in acute and subacute schizophrenia, organic psychosis, psychomotor agitation, manic-depressive states, neuroses, and other diseases. Assign in mild cases of the disease at 0.05 - 0.1 g - (50 - 100 mg) per day; in more severe cases, 0.15 - 0.6 g per day.
In outpatient practice for the treatment of borderline conditions, thioridazine is used at a dose of 40-100 mg per day. With small doses, a stimulating and antidepressant effect is more pronounced, with a increase in dose, the sedative effect increases.
For neurasthenia, irritability, anxiety, neurogenic functional gastrointestinal and cardiovascular disorders, chronic sleep disorders, 0.005-0.01 to 0.025 g 2 to 3 times a day is prescribed, and 0.025 for premenstrual nervous tension and menopausal disorders. g 1 - 2 times a day.
Children with psychopathic behavior, irritability, anxiety, night fears, etc., are prescribed in 0.005-0.01 g (5-10 mg) 2 to 3 times a day; the daily dose for children of preschool and early school age is 10–30 mg, and for older children it is up to 40–60 mg.
Contraindications: coma, allergic reactions and changes in the blood picture when using other drugs. There are indications that long-term use of thioridazine may develop toxic retinopathy.
Method of issuance: dragee containing 0.01; 0.025 and 0.1 g of the drug. For children's practice - 0.2% suspension (2 mg in 1 ml).
Storage: List B.